U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Monoclonal Antibody 90.12 Recognizes a Novel B Cell Surface Antigen Upregulated on Both Activated and Apoptotic Lymphocytes
  1. Licensing and Collaboration Opportunities

Monoclonal Antibody 90.12 Recognizes a Novel B Cell Surface Antigen Upregulated on Both Activated and Apoptotic Lymphocytes

Monoclonal antibody 90.12 recognizes a molecule expressed on the surface of a subset of B lymphocytes and on all types of blood cells. This antigen is increased upon stimulation of B and T lymphocytes as well as on cells undergoing programmed cell death. Amino acid sequencing of the beginning of the protein suggests that it is a member of the S100 family of calcium binding proteins.

Inventors:
Marjorie Shapiro

Intellectual Property:

Publications:
MA Shapiro, SP Fitzsimmons, and KJ Clark, "Characterization of a B cell surface antigen with homology to the S100 protein MRP8," Biochem. Biophys. Res. Commun. 1999 Sep 16 263(1):17-22.
KJ Clark, M Monser, KE Stein, and MA Shapiro, "A novel activation induced lymphocyte surface antigen, 90.12, is also expressed on apoptotic cells," Scand. J. Immunol. 2000 Feb 51(2):155-63.

Licensing Contact:
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4561

OTT Reference No: E-2004-019
Updated: Feb 1, 2005

Back to Top